Compare Hershey Co (HSY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Neurocrine Biosciences Inc — how do they compare? Hershey Co trades at $182.89 (market cap $36.56B), while Neurocrine Biosciences Inc trades at $157.17 (market cap $16.46B). The key difference: Hershey Co is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Hershey Co pays a 3.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HSY | NBIX | |
|---|---|---|
Market Cap | $36.56B | $16.46B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $185.50 |
52-Week Low | $162.31 | $123.10 |
Enterprise Value | $41.70B | $16.48B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $182.75, up 0.22% with a bullish technical signal and strong fundamental momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth trends upward to $11.69 billion in 2025. Analyst consensus targets $196.78 with 69% hold ratings, reflecting cautious optimism amid margin recovery from favorable cocoa contracts and dividend growth.
The outlook remains positive with earnings rebound and pricing power, though risks include volume declines and competitive pressures. Current valuation at 24.86 P/E appears reasonable given 32.81% ROE and improving cash flow trends. Institutional sentiment is mixed with recent insider sales offset by upward guidance revisions.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
